58
Views
415
CrossRef citations to date
0
Altmetric
Cell Growth and Development

ADD1/SREBP-1c Is Required in the Activation of Hepatic Lipogenic Gene Expression by Glucose

, , , , , , , , , & show all
Pages 3760-3768 | Received 21 Sep 1998, Accepted 28 Jan 1999, Published online: 28 Mar 2023
 

Abstract

The transcription of genes encoding proteins involved in the hepatic synthesis of lipids from glucose is strongly stimulated by carbohydrate feeding. It is now well established that in the liver, glucose is the main activator of the expression of this group of genes, with insulin having only a permissive role. While ADD1/SREBP-1 has been implicated in lipogenic gene expression through temporal association with food intake and ectopic gain-of-function experiments, no genetic evidence for a requirement for this factor in glucose-mediated gene expression has been established. We show here that the transcription of ADD1/SREBP-1c in primary cultures of hepatocytes is controlled positively by insulin and negatively by glucagon and cyclic AMP, establishing a link between this transcription factor and carbohydrate availability. Using adenovirus-mediated transfection of a powerful dominant negative form of ADD1/SREBP-1c in rat hepatocytes, we demonstrate that this factor is absolutely necessary for the stimulation by glucose of l-pyruvate kinase, fatty acid synthase, S14, and acetyl coenzyme A carboxylase gene expression. These results demonstrate that ADD1/SREBP-1c plays a crucial role in mediating the expression of lipogenic genes induced by glucose and insulin.

ACKNOWLEDGMENTS

We thank Jack Gauldie (McMaster University) for the generous gift of PDK6 and Marc Eloit (URA INRA, ENVA, Maisons-Alfort, France) for Ad βgal-nls.

Marc Foretz is a recipient of a doctoral fellowship from the Ministère de l’Enseignement Supérieur et de la Recherche. Pascal Ferré is financed by the Centre National de la Recherche Scientifique. This work was supported in part by the grant 97/3011 from the EEC Fair program, by the Institut Necker, and by the Association Francaise des Myopathies.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.